Morphic Therapeutic, Inc. (a Wholly Owned Subsidiary Of Eli Lilly And Company)
Clinical trials sponsored by Morphic Therapeutic, Inc. (a Wholly Owned Subsidiary Of Eli Lilly And Company), explained in plain language.
-
New oral drug shows promise for ulcerative colitis in early trial
Disease control CompletedThis study tested an experimental pill called MORF-057 in 39 adults with moderate to severe ulcerative colitis. The drug aims to reduce gut inflammation by blocking a specific protein. Researchers measured changes in colon tissue health and symptom scores after 12 weeks of treatm…
Phase: PHASE2 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Healthy volunteers test new drug MORF-440 for safety
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug, MORF-440, in 80 healthy adults. Participants received either a single dose or multiple doses to see how the body handles it and if any side effects occur. The goal was not to treat a disease but to gather important safety in…
Phase: PHASE1 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC